Tumour exosomes can also specifically bind and sequester therapeutic monoclonal antibodies (mAbs) thereby preventing binding of the mAb to the tumour cells and the expected downstream cytotoxicity by immune effector cells, as seen for HER2+ breast cancer cell lines treated with trastuzumab (Herceptin) [166]. The gene discussed is ERBB2; the disease is neoplasm.